CE Mark for Therapeutic Robot Device

Medtech company Axinesis has received CE mark approval (Directive 93/42/EEC) for its REAPlan interactive robotic device which is dedicated to the rehabilitation of impaired upper limbs of stroke patients and cerebral palsy children. Following evaluation on more than 300 patients the company, a spin-off from the Université catholique de Louvain (UCL, Belgium), is poised to begin immediate sales and distribution in select EU countries:

"This is an important milestone in our mission to provide state-of-the-art technologies dedicated to the rehabilitation of brain-injured patients," said company CEO Eric Hanesse. CEO of Axinesis. "The continual requests from customers for products enhancing patients' rehabilitation and the feedbacks of users on this project have been exceptional. We are very pleased to offer an innovative high-end technology, for a very affordable investment, to the European rehabilitation community and expand the clinical options available to all.  Robotics, integrated in rehabilitation programs, enable stroke patients to accomplish significant numbers of moves with their arms, fostering a natural reconstruction process of the brain, called neuroplasticity. Based on our current data and results, REAplan can help over 5 million people worldwide, left permanently disabled after a stroke event*, as well as children affected by the most common childhood disability, cerebral palsy." 

*Sources : World Health Organization (2004). Atlas of Heart Disease and Stroke / International Cardiovascular Disease Statistics (2007 Update)